Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine.

The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.

Pulmokine has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH. Funding sources include equity investment and NIH grants. We pursue in-licensing and partnership opportunities related to pulmonary and cardiovascular diseases.

Pulmonary drug research and testing pose a unique set of challenges. We are offering our proprietary discoveries and solutions to other companies in our field, in the form of fee-for-service work services and products for pre-clinical efficacy studies of pulmonary drugs. Our capabilities include measurement of pulmonary function, telemetry pressure monitoring, measurement of pressure volume loops, and drug delivery by inhalation.

In addition, Pulmokine is developing a novel class of kinase inhibitors through in silico modeling and in vitro screening.

Pulmokine’s inhaled drug candidate PK10571, for the treatment of pulmonary hypertension, is partnered with Gossamer Bio.